These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Wen PY; Reardon DA Nat Rev Neurol; 2016 Feb; 12(2):69-70. PubMed ID: 26782337 [No Abstract] [Full Text] [Related]
4. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485 [TBL] [Abstract][Full Text] [Related]
5. [An evidence based strategy for WHO Grade II Gliomas]. Narita Y No Shinkei Geka; 2013 Jul; 41(7):565-81. PubMed ID: 23824347 [No Abstract] [Full Text] [Related]
6. Updating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classification. Komori T Brain Tumor Pathol; 2020 Jan; 37(1):1-4. PubMed ID: 32060660 [No Abstract] [Full Text] [Related]
11. Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. von Deimling A; Ono T; Shirahata M; Louis DN Semin Neurol; 2018 Feb; 38(1):19-23. PubMed ID: 29548048 [TBL] [Abstract][Full Text] [Related]
12. Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016. Sasaki H; Yoshida K Neurol Med Chir (Tokyo); 2017 Dec; 57(12):658-666. PubMed ID: 28845038 [TBL] [Abstract][Full Text] [Related]
13. Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies. Delgado-López PD; Corrales-García EM; Martino J; Lastra-Aras E; Dueñas-Polo MT Clin Transl Oncol; 2017 Aug; 19(8):931-944. PubMed ID: 28255650 [TBL] [Abstract][Full Text] [Related]
14. [Clinico-pathological and molecular aspects of diagnostic and prognostic value in gliomas]. Ortega-Aznar A; Jimenez-Leon P; Martinez E; Romero-Vidal FJ Rev Neurol; 2013 Feb; 56(3):161-70. PubMed ID: 23359078 [TBL] [Abstract][Full Text] [Related]
16. Natural history of incidental World Health Organization grade II gliomas. Pallud J; Fontaine D; Duffau H; Mandonnet E; Sanai N; Taillandier L; Peruzzi P; Guillevin R; Bauchet L; Bernier V; Baron MH; Guyotat J; Capelle L Ann Neurol; 2010 Nov; 68(5):727-33. PubMed ID: 21031584 [TBL] [Abstract][Full Text] [Related]
17. [Modern approach to WHO grade II glioma classification and treatment--review of the literature]. Recławowicz D; Stempniewicz M; Biernat W; Słoniewski P Neurol Neurochir Pol; 2008; 42(6):536-45. PubMed ID: 19235107 [TBL] [Abstract][Full Text] [Related]
18. New developments and controversies in the neuropathology of malignant gliomas. Wiestler OD; Schmidt MC; von Deimling A; Reifenberger G; Deckert-Schlüter M; Radner H; Pietsch T Front Radiat Ther Oncol; 1999; 33():123-38. PubMed ID: 10549483 [No Abstract] [Full Text] [Related]
19. Ultrastructural cytopathology of human cerebral gliomas. Hossmann KA; Wechsler W Oncology; 1971; 25(5):455-80. PubMed ID: 4335473 [No Abstract] [Full Text] [Related]
20. Is H3 K27M mutation testing relevant in the diagnostic routine of WHO grade 4 gliomas exclusively located in the corpus callosum in adults? Paoli C; Segard S; Burel-Vandenbos F J Neurooncol; 2021 Dec; 155(3):383-384. PubMed ID: 34800209 [No Abstract] [Full Text] [Related] [Next] [New Search]